NEW MJ NEWS

Jushi Holdings Inc. to Report First Quarter 2024 Financial Results on May 9, 2024

Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, announced that it expects to report its financial results for the first quarter ended March 31, 2024, after the market closes on Thursday, May 9, 2024.

Management will host a conference call and audio webcast on Thursday, May 9, 2024, at 4:30 p.m. ET to discuss the Company’s financial results.

Event:

First Quarter 2024 Financial Results Conference Call

Date:

Thursday, May 9, 2024

Time:

4:30 p.m. Eastern Time

Live Call:

1-877-407-0792 (U.S. & Canada Toll-Free)

Conference ID

13745557

Webcast:

Register

For interested individuals unable to join the conference call, a webcast of the call will be available for one month following the call and can be accessed via webcast on Jushi’s Investor Relations website.

About Jushi Holdings Inc.

We are a vertically integrated cannabis company led by an industry-leading management team. Jushi is focused on building a multi-state portfolio of branded cannabis assets through opportunistic acquisitions, distressed workouts, and competitive applications. Jushi strives to maximize shareholder value while delivering high-quality products across all levels of the cannabis ecosystem. For more information, visit jushico.com or our social media channels, Instagram, Facebook, X, and LinkedIn.

For further information, please contact:

Investor Relations
Lisa Forman
Director of Investor Relations
617-767-4419
investors@jushico.com


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$VAPO Files Form 8-K/A

Form 8-K/A for VAPORIN, INC. 13-Nov-2014 Financial Statements and Exhibits Item 9.01…

GT Biopharma, Inc. (GTBP) Announces it has Completed Enrollment in Proof-of-concept Clinical Trial for its Novel Treatment

GT Biopharma, Inc. Announces it has Completed Enrollment in Proof-of-concept Clinical Trial…

 Tetra Bio-Pharma Inc. (TBPMF) Provides Management Update on COVID-19

Tetra Bio-Pharma Provides Management Update on COVID-19  Tetra Bio-Pharma Inc. (“Tetra” or…

Tetra Bio-Pharma Inc. (TBPMF) Maps Out Cannabinoid Metabolites in Humans

Tetra Bio-Pharma Maps Out Cannabinoid Metabolites in Humans Following Inhalation of QIXLEEF…